Ibuprofen is one of the most commonly used painkillers in the US and is often used for muscle pain, headaches and menstrual pain.
The recent research suggests that the painkiller could also be helpful in lowering certain cancer risks.
According to the PLCO study, ibuprofen can significantly reduce the risks of endometrial and colon cancer.
The data from 42,000 women showed that those who took at least 30 ibuprofen tablets a month had a 25 percent lower risk of developing endometrial cancer compared to other users who used the painkiller occasionally.
Fighting cancer caused by inflammation
Because they belong to the family of nonsteroidal anti-inflammatory drugs (NSAIDs), the link between the tablet and cancer prevention is well known.
When it comes to lowering cancer risks, it works by inhibiting enzymes called cyclooxygenases (COX), specifically COX-2, which is responsible for inflammation and cancer cell growth.
Furthermore, at the genetic level, Ibuprofen also works by suppressing specific genes such as HIF-1α that help cancer cells survive under harsh conditions and resist chemotherapy.
Broader potential of Ibuprofen
The evidence also suggests the broad-spectrum benefit of ibuprofen in preventing the various types of cancer, including colon, breast, lung and prostate. In the case of colon cancer, it reduces the recurrence rate.
Despite the promising results, experts warn against self-medicating with ibuprofen for cancer prevention, as it can cause stomach ulcers, kidney damage, intestinal bleeding, cardiovascular diseases such as strokes and heart attacks.
Therefore, further extensive research is needed to determine its potential benefits and optimize its use in the future.
